Wall Street analysts expect that Adamas Pharmaceuticals Inc (NASDAQ:ADMS) will post sales of $15.18 million for the current quarter, according to Zacks Investment Research. Five analysts have provided estimates for Adamas Pharmaceuticals’ earnings, with the highest sales estimate coming in at $16.00 million and the lowest estimate coming in at $14.40 million. Adamas Pharmaceuticals posted sales of $13.32 million during the same quarter last year, which would indicate a positive year-over-year growth rate of 14%. The company is expected to issue its next earnings report on Monday, March 2nd.
According to Zacks, analysts expect that Adamas Pharmaceuticals will report full-year sales of $53.47 million for the current fiscal year, with estimates ranging from $52.70 million to $54.30 million. For the next year, analysts anticipate that the business will post sales of $92.03 million, with estimates ranging from $65.20 million to $123.00 million. Zacks Investment Research’s sales averages are an average based on a survey of sell-side research analysts that follow Adamas Pharmaceuticals.
Adamas Pharmaceuticals (NASDAQ:ADMS) last issued its earnings results on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). The company had revenue of $13.93 million for the quarter, compared to the consensus estimate of $14.36 million. Adamas Pharmaceuticals had a negative return on equity of 205.30% and a negative net margin of 215.09%.
Several equities research analysts have commented on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $10.00 target price (down previously from $30.00) on shares of Adamas Pharmaceuticals in a research note on Wednesday, December 18th. Cantor Fitzgerald reiterated a “neutral” rating and issued a $7.00 target price (down from $8.00) on shares of Adamas Pharmaceuticals in a report on Tuesday, December 17th. JMP Securities reduced their price target on shares of Adamas Pharmaceuticals to $16.00 and set an “outperform” rating on the stock in a research report on Friday, November 8th. Needham & Company LLC reissued a “hold” rating on shares of Adamas Pharmaceuticals in a report on Tuesday, December 17th. Finally, Zacks Investment Research cut shares of Adamas Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Wednesday, October 16th. Three research analysts have rated the stock with a sell rating, five have assigned a hold rating and five have given a buy rating to the company’s stock. Adamas Pharmaceuticals currently has an average rating of “Hold” and an average target price of $14.63.
Adamas Pharmaceuticals stock traded up $0.09 during midday trading on Wednesday, hitting $3.74. 560,677 shares of the stock were exchanged, compared to its average volume of 919,090. The company has a fifty day simple moving average of $5.46 and a two-hundred day simple moving average of $5.51. Adamas Pharmaceuticals has a 52 week low of $3.35 and a 52 week high of $12.57. The stock has a market capitalization of $104.20 million, a PE ratio of -0.77 and a beta of 1.78. The company has a quick ratio of 6.15, a current ratio of 6.35 and a debt-to-equity ratio of 6.72.
Hedge funds and other institutional investors have recently bought and sold shares of the stock. Quantamental Technologies LLC bought a new position in Adamas Pharmaceuticals in the second quarter valued at approximately $25,000. Public Employees Retirement System of Ohio acquired a new stake in shares of Adamas Pharmaceuticals during the third quarter worth $56,000. Dowling & Yahnke LLC bought a new stake in Adamas Pharmaceuticals in the 3rd quarter valued at $66,000. Advisor Group Inc. lifted its position in Adamas Pharmaceuticals by 53.4% in the 2nd quarter. Advisor Group Inc. now owns 11,200 shares of the specialty pharmaceutical company’s stock valued at $69,000 after acquiring an additional 3,900 shares in the last quarter. Finally, DekaBank Deutsche Girozentrale lifted its position in Adamas Pharmaceuticals by 63.8% in the 2nd quarter. DekaBank Deutsche Girozentrale now owns 15,400 shares of the specialty pharmaceutical company’s stock valued at $91,000 after acquiring an additional 6,000 shares in the last quarter. 51.99% of the stock is owned by institutional investors and hedge funds.
About Adamas Pharmaceuticals
Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.
Recommended Story: What member countries make up the G-20?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Adamas Pharmaceuticals Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com’s FREE daily email newsletter.